SCHEMBL9909298

SCHEMBL9909298

COC(=O)c1ccc2c(Cl)cnc(-c3c(OC)cccc3OC)c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 4/20 0.49
KMT2A Q03164 3/20 0.45
MAPT P10636 3/20 0.45
MEN1 O00255 2/20 0.45
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
GLA P06280 1/20 0.41
CSNK2A1 P68400 1/20 0.41
TP53 P04637 1/20 0.40
PLG P00747 2/20 0.40
PLAU P00749 2/20 0.40
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
NR1H4 Q96RI1 2/20 0.39
PLAT P00750 1/20 0.39
ALPL P05186 1/20 0.39
HSP90AA1 P07900 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KCNQ3 O43525 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907999 0.93 HTR5A (0.48) HTR5AKMT2AMAPTMEN1RAB9A
SCHEMBL9909263 0.92 HTR5A (0.60) HTR5AKMT2AMAPTMEN1RAB9A
SCHEMBL9909315 0.89 HTR5A (0.50) HTR5AKMT2AMEN1PLGPLAU
SCHEMBL9907766 0.87 HTR5A (0.52) HTR5ACSNK2A1TP53NR1H2NR1H3
SCHEMBL9909293 0.85 HTR5A (0.60) HTR5AKMT2AMAPTMEN1RAB9A
SCHEMBL9909312 0.85 HTR5A (0.47) HTR5AKMT2AMAPTMEN1RAB9A
SCHEMBL15500531 0.85 HTR5A (0.44) HTR5AKMT2AMAPTMEN1RAB9A
SCHEMBL9907660 0.84 HTR5A (0.60) HTR5AMAPTCSNK2A1TP53NR1H2
SCHEMBL9909317 0.83 HTR5A (0.72) HTR5APLGPLAUPLAT
SCHEMBL9908010 0.83 HTR5A (0.49) HTR5APLGPLAUPLATHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E HTR5A 1/4885KMT2A 1729/4885MAPT 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.